Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference: “Active Control of MALDI TOF Mass Spectra Acquisition With Internal Standards for Improved Quantitative Serum Protein Profiles”
Salzburg, Austria…Nicholas Dupuis, Ph.D, of Biodesix®, Inc. is speaking today at the MSACL 3rd Annual Conference, where he is the chairperson of the Protein Quantitation track. Dupuis is a Senior Scientist at Biodesix, where he leads technology transfer and assay development for proteomic products using Biodesix’ proprietary mass spectrometry based assays.
Where: Papageno Hall, Salzburg Congress Center
When: 11:15 AM
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) is a rapid, reproducible, and sensitive tool for measuring protein profiles in biological fluids. Profiling has many potential clinical applications, including diagnosis, predicting disease aggressiveness, and assessing differential therapeutic benefit for cancer patients. In this study we: 1) incorporate multiple internal standards to allow quantitative comparisons between samples and 2) use a proportional-integral-derivative (PID) control algorithm to optimize spectral quality during acquisition. This approach expands the potential applications of MALDI profiling, markedly enhances spectral quality, and reduces reliance on operator intervention during acquisition.
Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat™ and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.